• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    5/30/25 4:15:35 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    false000004907100000490712025-05-302025-05-30

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
     

    FORM 8-K
     
     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 30, 2025 (May 30, 2025)
     
     

    Humana Inc.
    (Exact name of registrant as specified in its charter)
     


     
             
    DE
     
    1-5975
     
    61-0647538
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)

    500 W. Main Street, Louisville, KY 40202
    (Address of principal executive offices, and zip code)
    (502) 580-1000
    Registrant’s telephone number, including area code
     
    (Former name or former address, if changed since last report)
     
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
     
             
    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock
     
    HUM
     
    New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     
     


     
    Item 1.01
    Entry into a Material Definitive Agreement.

    On May 30, 2025, Humana Inc. (the “Company”) entered into a $5.0 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Bank National Association, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “Revolving Credit Agreement”), which amends and restates that certain existing unsecured revolving credit agreement, dated as of June 2, 2023, with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “Existing 5-Year Credit Agreement”). The Revolving Credit Agreement (i) increases the amount of the commitments under the Existing 5-Year Credit Agreement from $2.642 billion to $5.0 billion and (ii) replaces the Company’s existing 364-day $2.1 billion unsecured revolving credit agreement, dated as of May 31, 2024, with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners, which has expired in accordance with its terms.
    Loans under the Revolving Credit Agreement bear interest at Term SOFR, Daily Simple SOFR or the base rate plus a spread. The Company will pay an annual facility fee under the Revolving Credit Agreement regardless of utilization.
    The Revolving Credit Agreement contains customary covenants, including a maximum debt to capitalization covenant, as well as customary events of default. The terms of the Revolving Credit Agreement also include standard provisions related to conditions of borrowing, including customary representations and warranties. In addition, the Revolving Credit Agreement permits the incurrence up to $1.0 billion of incremental commitments.
    We have other relationships, including financial advisory and banking, with some parties to the Revolving Credit Agreement.
    As of May 30, 2025, we have no borrowings outstanding under the Revolving Credit Agreement and approximately $14.7 million of issued and undrawn letters of credit under the Revolving Credit Agreement. Accordingly, as of May 30, 2025, we have approximately $4.98 billion of remaining borrowing capacity under the Revolving Credit Agreement.
    The foregoing description of the Revolving Credit Agreement does not purport to be complete. For an understanding of the terms and provisions of the Revolving Credit Agreement, reference should be made to the copy of the Revolving Credit Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the six months ending June 30, 2025.
     
    Item 2.03
    Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

    The information described above under Item 1.01 of this Current Report on Form 8-K is also responsive to Item 2.03 of this Current Report on Form 8-K and is incorporated by reference into this Item 2.03.
     
    Item 9.01
    Financial Statements and Exhibits.

    (d) Exhibits:
     
         
    Exhibit
    No.
     
    Description
       
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     
    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
     
         
    HUMANA INC.
       
    BY:
     
    /s/ John-Paul Felter
     
     
    John-Paul Felter
     
     
    Senior Vice President, Chief Accounting Officer and Controller
    (Principal Accounting Officer)

    Dated: May 30, 2025
    Get the next $HUM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    12/5/2025$313.00Hold → Buy
    Jefferies
    10/14/2025$235.00Sell
    Goldman
    9/22/2025$295.00In-line
    Evercore ISI
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    More analyst ratings

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/21/24 10:37:23 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

    Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions. A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023. The study also compared the demographic and clinical characteristics of members with type 2 diabetes who used CGMs with those who did not in 2023, finding that t

    3/12/26 9:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Completes Aggregate $1.0 Billion Fixed-to-Fixed Rate Junior Subordinated Notes Offering

    Humana Inc. (the "company") (NYSE:HUM) announced today the completion of its public offering of $1.0 billion in aggregate principal amount of fixed-to-fixed rate junior subordinated notes due 2056, at 6.625 percent of the principal amount (the "Junior Subordinated Notes Offering"). The company expects net proceeds from the Junior Subordinated Notes Offering will be approximately $986 million after deducting underwriters' discounts and estimated offering expenses. The company intends to use the net proceeds from the Junior Subordinated Notes Offering for general corporate purposes, which may include the repayment of existing indebtedness, including borrowings under its commercial paper pro

    3/9/26 5:00:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    AM Best Assigns Issue Credit Rating to Humana Inc.'s New Junior Subordinated Notes

    AM Best has assigned a Long-Term Issue Credit Rating of "bbb-" (Good) to the $1 billion, 6.625% fixed rate junior subordinated notes, due 2056, of Humana Inc. (Humana) (headquartered in Louisville, KY) (NYSE:HUM). The outlook assigned to this Credit Rating (rating) is stable. All other ratings of Humana and its subsidiaries remain unchanged. Humana expects to use the proceeds from the junior subordinated notes issuance for general corporate purposes, which may include repayment of existing indebtedness, including borrowings under its commercial paper program. AM Best expects the issuance to increase financial leverage slightly in the intermediate term. The company's financial leverage, as

    3/6/26 11:04:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Ventura Joseph C converted options into 1,035 units of Humana Common and covered exercise/tax liability with 478 units of Humana Common, increasing direct ownership by 3% to 17,087 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 5:09:07 PM ET
    $HUM
    Medical Specialities
    Health Care

    President, Insurance Renaudin George Ii covered exercise/tax liability with 419 units of Humana Common and converted options into 1,035 units of Humana Common, increasing direct ownership by 4% to 16,075 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 3:43:58 PM ET
    $HUM
    Medical Specialities
    Health Care

    SVP, Chief Accting Off & Cont. Felter John-Paul W. was granted 5,669 units of Humana Common, converted options into 165 units of Humana Common and covered exercise/tax liability with 84 units of Humana Common, increasing direct ownership by 332% to 7,484 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 4:04:34 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Humana from Overweight to Equal Weight and set a new price target of $290.00

    1/7/26 8:56:48 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    SEC Filings

    View All

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    3/9/26 4:22:23 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form DEFR14A filed by Humana Inc.

    DEFR14A - HUMANA INC (0000049071) (Filer)

    3/6/26 5:31:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Humana Inc.

    424B5 - HUMANA INC (0000049071) (Filer)

    3/6/26 4:33:29 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Leadership Updates

    Live Leadership Updates

    View All

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    National Mall of Pickleball Returns for Third Year with Expanded Footprint and New, Central Location

    The National Mall of Pickleball will celebrate America's most accessible sport and the game that serves all in the heart of the National Mall this September The Trust for the National Mall, Humana (NYSE:HUM), and the Humana Foundation announced today that the highly-anticipated National Mall of Pickleball is returning to America's Front Yard, the National Mall, for a third year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625316935/en/ From Friday, September 19 through Sunday, September 21, 2025, the general public can experience a weekend full of pickleball programming, activities, and community with captivating views o

    6/25/25 9:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Launches "Invite" Campaign to Inspire Active Aging Through Pickleball and Community Connection

    Humana Inc. (NYSE:HUM), a leading health and well-being company, is expanding its commitment to senior wellness with the launch of Invite, a new campaign designed to encourage older adults of all fitness levels to stay active, connected and engaged – starting with the fastest-growing sport in America: pickleball. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618737488/en/As part of Humana's new "Invite" campaign, the health and wellness company debuted a television spot featuring senior pickleball athletes extending an open invitation to others to join the fun, stay social, and support their physical and mental well-being. A

    6/18/25 8:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/16/24 4:29:43 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/14/24 10:02:59 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/13/24 5:06:27 PM ET
    $HUM
    Medical Specialities
    Health Care

    $HUM
    Financials

    Live finance-specific insights

    View All

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Inc. to Release Fourth Quarter 2025 Results on February 11, 2026

    Humana Inc. (NYSE:HUM) will release its financial results for the fourth quarter 2025 (4Q25), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on February 11, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026. A webcast of the 4Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/. If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIb3f01f81dd3b4f7cb8331d38dad89

    1/9/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care